The U.S. Food and Drug Administration announced it will relax certain rules for approving low-cost versions of some ...

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...

FRIDAY, Oct. 31, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) announced Wednesday that it will relax ...

Veterinary teams enhance feline diabetes management through personalized care, effective communication, and evolving treatment options for improved quality of life.

Sanofi Q3 sales beat estimates on strong Dupixent and new drug demand; reaffirms 2025 outlook with double-digit EPS growth ...

California's first insulin pens will be for sale two years after the governor’s promised delivery date in 2024.

Californians will be able to buy five packs of insulin pens for a maximum of $55 per pack, or $11 per pen, starting Jan. 1, ...

AI tools designed to make health care more efficient are ubiquitous, though many remain piecemeal and siloed, as researchers ...

California will offer CalRx-branded biosimilar insulin glargine pens for $11 per pen beginning January 1, 2026.

Starting next year, Californians with diabetes will be able to purchase state-branded insulin at steeply reduced prices, Gov. Gavin Newsom announced today. Long-acting insulin pens will be available ...

Biocon Biologics recently announced that it would manufacture and supply insulin glargine pens to Civica under a multi-year ...